Return to Today's science sparks archives

2013-04-01

Fig 1. Physicians who performed UD by log year and certification type.

Fig 1. Physicians who performed UD by log year and certification type.
  • Silberstein JL, Poon SA, Maschino AC, Lowrance WT, Garg T, Herr HW, Donat SM, Dalbagni G, Bochner BH, Sandhu JS

  • J Urol. 2013 Mar;189(3):1042-7.

2013-04-02

Fig 2a. Model-adjusted probability of nonattrition by risk scores for the dominant multivariate model, among 2,033 postgraduate year (PGY)-1 and PGY-2 residents.

Fig 2a. Model-adjusted probability of nonattrition by risk scores for the dominant multivariate model, among 2,033 postgraduate year (PGY)-1 and PGY-2 residents.
  • Sullivan MC, Yeo H, Roman SA, Ciarleglio MM, Cong X, Bell RH Jr, Sosa JA

  • J Am Coll Surg. 2013 Mar;216(3):461-71.

2013-04-03

Fig 1. Thermal images corresponding to power levels of 125, 250, 500, 1000, and 2000 mW and irradiation times of 12 min in a 5-mm slice taken in the center of imaging slab (IP1).

Fig 1. Thermal images corresponding to power levels of 125, 250, 500, 1000, and 2000 mW and irradiation times of 12 min in a 5-mm slice taken in the center of imaging slab (IP1).
  • Gultekin DH, Moeller L

  • Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):58-63.

2013-04-04

Fig 1. Axial view demonstrating contrast inside the vaginal cuff.

Fig 1. Axial view demonstrating contrast inside the vaginal cuff.
  • Shih KK, Milgrom SA, Abu-Rustum NR, Kollmeier MA, Gardner GJ, Tew WP, Barakat RR, Alektiar KM

  • Gynecol Oncol. 2013 Mar;128(3):535-9.

2013-04-05

Fig 2. Survival based on time from prior chemotherapy.

Fig 2. Survival based on time from prior chemotherapy.
  • Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J

  • Eur Urol. 2013 Apr;63(4):717-23.

2013-04-08

Fig. 2. Frequency of bilateral drainage by lymphoscintigraphy relative to the location of the primary lesion as assessed by hand-drawn schematics, and operative or pathological reports.

Fig. 2. Frequency of bilateral drainage by lymphoscintigraphy relative to the location of the primary lesion as assessed by hand-drawn schematics, and operative or pathological reports.
  • Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM Jr, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ 2nd, Van Le L, Trimble CL

  • Gynecol Oncol. 2013 Feb;128(2):155-9.

2013-04-09

Fig 1. Standard error of measurement (SEM) of Shame and Stigma full scale and subscales, with standardized score estimates and threshold parameters from graded response models (GRMs).

Fig 1. Standard error of measurement (SEM) of Shame and Stigma full scale and subscales, with standardized score estimates and threshold parameters from graded response models (GRMs).
  • Kissane DW, Patel SG, Baser RE, Bell R, Farberov M, Ostroff JS, Li Y, Singh B, Kraus DH, Shah JP

  • Head Neck. 2013 Feb;35(2):172-83.

2013-04-10

Fig 11. The completed pericardial and diaphragmatic reconstruction. Laterally, the diaphragm is secured by sutures placed around the ribs.

Fig 11. The completed pericardial and diaphragmatic reconstruction. Laterally, the diaphragm is secured by sutures placed around the ribs.
  • Yanagawa J, Rusch V

  • Thorac Surg Clin. 2013 Feb;23(1):73-87.

2013-04-11

Fig. 1. FACE-Q conceptual framework.

Fig. 1. FACE-Q conceptual framework.
  • Pusic AL, Klassen AF, Scott AM, Cano SJ

  • Clin Plast Surg. 2013 Apr;40(2):249-60.

2013-04-12

Fig. 3. Invasive ductal carcinoma NOS (H&E, ×4).

Fig. 3. Invasive ductal carcinoma NOS (H&E, ×4).
  • Corben AD

  • Surg Clin North Am. 2013 Apr;93(2):363-92.

2013-04-15

Fig. 1. BREAST-Q© conceptual framework.

Fig. 1. BREAST-Q© conceptual framework.
  • Cano SJ, Klassen AF, Scott AM, Pusic AL

  • Clin Plast Surg. 2013 Apr;40(2):287-96.

2013-04-16

1(b). RU-SKI 43 inhibition kinetics with purified Hhat. Each point represents mean ± s.d. (n = 2).

1(b). RU-SKI 43 inhibition kinetics with purified Hhat. Each point represents mean ± s.d. (n = 2).
  • Petrova E, Rios-Esteves J, Ouerfelli O, Glickman JF, Resh MD

  • Nat Chem Biol. 2013 Apr;9(4):247-9.

2013-04-17

Fig 3A. Schematic diagrams of promoters for the CYP19A1 gene. The relative tissue specificity for each promoter is listed. The skin/adipose I.4 promoter is highlighted in red.

Fig 3A. Schematic diagrams of promoters for the CYP19A1 gene. The relative tissue specificity for each promoter is listed. The skin/adipose I.4 promoter is highlighted in red.
  • Liu M, Ingle JN, Fridley BL, Buzdar AU, Robson ME, Kubo M, Wang L, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Goetz MP, Northfelt DW, Perez EA, Williard CV, Schaid DJ, Nakamura Y, Weinshilboum RM

  • Mol Endocrinol. 2013 Apr;27(4):657-70

2013-04-18

Fig 3. Plasma concentration:time profiles for three different days at 100 mg/m2. This graph demonstrates a stationary PK with negligible changes upon repeated dosing at weekly intervals.

Fig 3. Plasma concentration:time profiles for three different days at 100 mg/m2. This graph demonstrates a stationary PK with negligible changes upon repeated dosing at weekly intervals.
  • Konner J, Grisham RN, Park J, O'Connor OA, Cropp G, Johnson R, Hannah AL, Hensley ML, Sabbatini P, Mironov S, Danishefsky S, Hyman D, Spriggs DR, Dupont J, Aghajanian C

  • Invest New Drugs. 2012 Dec;30(6):2294-302

2013-04-19

Fig 1. Roles of sumoylated telomere proteins in Saccharomyces cerevisiae.

Fig 1. Roles of sumoylated telomere proteins in Saccharomyces cerevisiae.
  • Chung I, Zhao X

  • EMBO J. 2013 Mar 20;32(6):775-7.

2013-04-22

Fig 1.(H): Cutaneous squamous cell carcinoma (histology).

Fig 1.(H): Cutaneous squamous cell carcinoma (histology).
  • Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, Kim CC, McCormack CJ, Myskowski PL, Spleiss O, Trunzer K, Su F, Nelson B, Nolop KB, Grippo JF, Lee RJ, Klimek MJ, Troy JL, Joe AK

  • Oncologist. 2013;18(3):314-22.

2013-04-23

Fig 3. Signaling pathways mediated by FGFR3. FGF ligand binding to FGFR3 results in autophosphorylation of the receptor and activation of multiple downstream signaling pathways.

Fig 3. Signaling pathways mediated by FGFR3. FGF ligand binding to FGFR3 results in autophosphorylation of the receptor and activation of multiple downstream signaling pathways.
  • Iyer G, Milowsky MI

  • Urol Oncol. 2013 Apr;31(3):303-11.

2013-04-24

Fig 1. Estimated survival-time curves for biochemical relapse-free survival (bRFS), distant metastasis-free survival (DMFS), and prostate cancer-specific mortality (PCSM)

Fig 1. Estimated survival-time curves for biochemical relapse-free survival (bRFS), distant metastasis-free survival (DMFS), and prostate cancer-specific mortality (PCSM)
  • Spratt DE, Zumsteg Z, Ghadjar P, Pangasa M, Pei X, Fine SW, Yamada Y, Kollmeier M, Zelefsky MJ

  • Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1254-61.

2013-04-25

Fig 5. Dermoscopic images of dermatofibroma on thigh of 45-year-old woman.

Fig 5. Dermoscopic images of dermatofibroma on thigh of 45-year-old woman.
  • Pizzichetta MA, Talamini R, Marghoob AA, Soyer HP, Argenziano G, Bono R, Corradin MT, De Giorgi V, Gonzalez MA, Kolm I, Kopf AW, Malvehy J, Nami N, Oliviero M, Pellacani G, Puig S, Rabinovitz H, Rubegni P, Seidenari S, Stanganelli I, Veronesi A, Zalaudek I, Zampieri P, Menzies SW

  • J Am Acad Dermatol. 2013 Apr;68(4):552-9.

2013-04-26

Fig 2. Overall survival by Stage (I–III versus IV).

Fig 2. Overall survival by Stage (I–III versus IV).
  • Hyman DM, Bakios L, Gualtiere G, Carr C, Grisham RN, Makker V, Sonoda Y, Aghajanian C, Jewell EL

  • Gynecol Oncol. 2013 Apr;129(1):58-62.

2013-04-29

Fig 2. Differences in responses of the respondents according to priorities. Black bars, trained surgeon; dark gray bars, trainee; light gray bars, medical student.

Fig 2. Differences in responses of the respondents according to priorities. Black bars, trained surgeon; dark gray bars, trainee; light gray bars, medical student.
  • Henry JA, Groen RS, Price RR, Nwomeh BC, Kingham TP, Hardy MA, Kushner AL

  • Surgery. 2013 Apr;153(4):445-54.

2013-04-30

Fig 1. Mean ± standard deviation and median frequency of benign renal tumors and clear cell renal carcinoma (ccRCC) in studies of patients with renal masses.

Fig 1. Mean ± standard deviation and median frequency of benign renal tumors and clear cell renal carcinoma (ccRCC) in studies of patients with renal masses.
  • Corcoran AT, Russo P, Lowrance WT, Asnis-Alibozek A, Libertino JA, Pryma DA, Divgi CR, Uzzo RG

  • Urology. 2013 Apr;81(4):707-13.

2013-05-01

Fig 3c. Three-dimensional projection of principal component analysis (PCA) of ~8000 probesets expressed in normal hematopoietic precursors (HSCs; common myeloid progenitors (CMPs); megakaryocyte-erythroid progenitors (MEPs); GMPs), LH and LG demonstrate that the leukemia stem cells possess unique gene expression programs.

Fig 3c. Three-dimensional projection of principal component analysis (PCA) of ~8000 probesets expressed in normal hematopoietic precursors (HSCs; common myeloid progenitors (CMPs); megakaryocyte-erythroid progenitors (MEPs); GMPs), LH and LG demonstrate that the leukemia stem cells possess unique gene expression programs.
  • Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJ, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA

  • Leukemia. 2013 Apr;27(4):852-60.

2013-05-02

Fig 1.  Major capsular and vascular invasion with high mitotic activity confirming diagnosis of parathyroid carcinoma.

Fig 1. Major capsular and vascular invasion with high mitotic activity confirming diagnosis of parathyroid carcinoma.
  • Mohebati A, Shaha A, Shah J

  • Hematol Oncol Clin North Am. 2012 Dec;26(6):1221-38.

2013-05-03

Fig 1a. Colonoscopy images from mice before and after 9 cycles of DSS.

Fig 1a. Colonoscopy images from mice before and after 9 cycles of DSS.
  • Wang Y, Velho S, Vakiani E, Peng S, Bass AJ, Chu GC, Gierut J, Bugni JM, Der CJ, Philips M, Solit DB, Haigis KM

  • Cancer Discov. 2013 Mar;3(3):294-307.

2013-05-06

Fig 1. Progression-free survival is illustrated (n = 47). At 2 years, 75% of patients remained progression-free (95% confidence interval, 67%-91%); and, at 3 years, 57% of patients remained progression-free (95% confidence interval, 44%-74%).

Fig 1. Progression-free survival is illustrated (n = 47). At 2 years, 75% of patients remained progression-free (95% confidence interval, 67%-91%); and, at 3 years, 57% of patients remained progression-free (95% confidence interval, 44%-74%).
  • Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, George S, Soslow RA, Baker LH

  • Cancer. 2013 Apr 15;119(8):1555-61.

2013-05-07

Fig 3. Spindle cell RMS with TEAD1-NCOA2 fusion. Tumor from a 4-week-old baby boy who was born with a chest wall mass (case RMS4). A: It is composed of short fascicles of spindle cells that have somewhat myofibroblastic appearance, infiltrating adjacent skeletal muscle.

Fig 3. Spindle cell RMS with TEAD1-NCOA2 fusion. Tumor from a 4-week-old baby boy who was born with a chest wall mass (case RMS4). A: It is composed of short fascicles of spindle cells that have somewhat myofibroblastic appearance, infiltrating adjacent skeletal muscle.
  • Mosquera JM, Sboner A, Zhang L, Kitabayashi N, Chen CL, Sung YS, Wexler LH, Laquaglia MP, Edelman M, Sreekantaiah C, Rubin MA, Antonescu CR

  • Genes Chromosomes Cancer. 2013 Jun;52(6):538-50.

2013-05-08

Fig 4. Example of stereotactic body radiotherapy plan for vertebral body metastasis from Ewing sarcoma.

Fig 4. Example of stereotactic body radiotherapy plan for vertebral body metastasis from Ewing sarcoma.
  • Merchant TE, Hodgson D, Laack NN, Wolden S, Indelicato DJ, Kalapurakal JA; COG Radiation Oncology Discipline Committee

  • Pediatr Blood Cancer. 2013 Jun;60(6):1037-43.

2013-05-09

Fig 1. CBCT images of the motion phantom using various acquisition modes.

Fig 1. CBCT images of the motion phantom using various acquisition modes.
  • Kincaid RE, Yorke ED, Goodman KA, Rimner A, Wu AJ, Mageras GS

  • Med Phys. 2013 Apr;40(4):041717.

2013-05-10

Fig 3. Desmoplastic melanoma, pure type.A. Amelanotic spindle cell melanoma is associated with collagenous stroma and lymphocytic aggregates.

Fig 3. Desmoplastic melanoma, pure type.A. Amelanotic spindle cell melanoma is associated with collagenous stroma and lymphocytic aggregates.
  • Chen LL, Jaimes N, Barker CA, Busam KJ, Marghoob AA

  • J Am Acad Dermatol. 2013 May;68(5):825-33.

2013-05-13

Fig 1. Neoplastic cells with round nuclei, coarse chromatin pattern, and distinct prominent nucleoli were noted in most cells. Occasional interspersed pleomorphic nuclei noted. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

Fig 1. Neoplastic cells with round nuclei, coarse chromatin pattern, and distinct prominent nucleoli were noted in most cells. Occasional interspersed pleomorphic nuclei noted. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
  • Lin O, Koreishi A, Brandt SM, Arcila M, Teruya-Feldstein J

  • Diagn Cytopathol. 2013 May;41(5):404-7.

2013-05-14

Fig 1a. Venn analysis showing the gene expression changes induced by SN12C in the lung stromal compartment. The list shows the genes that were significantly upregulated by SN12C in the lung stroma in comparison with normal mouse lung and lung stroma of mice injected with LM2 cells.

Fig 1a. Venn analysis showing the gene expression changes induced by SN12C in the lung stromal compartment. The list shows the genes that were significantly upregulated by SN12C in the lung stroma in comparison with normal mouse lung and lung stroma of mice injected with LM2 cells.
  • López-Lago MA, Posner S, Thodima VJ, Molina AM, Motzer RJ, Chaganti RS

  • Oncogene. 2013 Apr 4;32(14):1752-60.

2013-05-15

Fig 1a. Immunophenotyping and gene-expression of Eμ-ALL01 cells.

Fig 1a. Immunophenotyping and gene-expression of Eμ-ALL01 cells.
  • Davila ML, Kloss CC, Gunset G, Sadelain M

  • PLoS One. 2013 Apr 9;8(4):e61338.
Open Access button

2013-05-17

Fig 2. miRNAs have oncogene and tumor suppressor activity in natural killer (NK) cells.

Fig 2. miRNAs have oncogene and tumor suppressor activity in natural killer (NK) cells.
  • Beaulieu AM, Bezman NA, Lee JE, Matloubian M, Sun JC, Lanier LL

  • Immunol Rev. 2013 May;253(1):40-52.

2013-05-20

Fig. 4. 131I uptake of WRO cells after transfection of 20 nmol of siRNABRAF when grown in three different TSH environments: no TSH (H5), physiological TSH (H6), and media supplemented with ×50 the physiological concentration of TSH (supratherapeutic). 131

Fig. 4. 131I uptake of WRO cells after transfection of 20 nmol of siRNABRAF when grown in three different TSH environments: no TSH (H5), physiological TSH (H6), and media supplemented with ×50 the physiological concentration of TSH (supratherapeutic). 131
  • Kleiman DA, Buitrago D, Crowley MJ, Beninato T, Veach AJ, Zanzonico PB, Jin M, Fahey TJ 3rd, Zarnegar R

  • J Surg Res. 2013 Jun 1;182(1):85-93.

2013-05-21

Fig 2. Percentage of endoscopic BPH procedures performed as electrosurgical TURP (CPT 52601, 52612 or 52614) (solid curve) and LP (CPT 52648 or CPT 52649) (dashed line) by year of urologist (re)certification.

Fig 2. Percentage of endoscopic BPH procedures performed as electrosurgical TURP (CPT 52601, 52612 or 52614) (solid curve) and LP (CPT 52648 or CPT 52649) (dashed line) by year of urologist (re)certification.
  • Lowrance WT, Southwick A, Maschino AC, Sandhu JS

  • J Urol. 2013 May;189(5):1811-6.

2013-05-22

Fig 1. Schematic of BrachyView rectal probe. Three side-by-side Medipix detectors are placed inside of the TRUS probe and inferiorly to the prostate gland.

Fig 1. Schematic of BrachyView rectal probe. Three side-by-side Medipix detectors are placed inside of the TRUS probe and inferiorly to the prostate gland.
  • Petasecca M, Loo KJ, Safavi-Naeini M, Han Z, Metcalfe PE, Meikle S, Pospisil S, Jakubek J, Bucci JA, Zaider M, Lerch ML, Qi Y, Rosenfeld AB

  • Med Phys. 2013 Apr;40(4):041709.

2013-05-23

Fig 1. CONSORT diagram showing patient population from which semen analysis data were derived. HPT XRT, hypothalamic-pituitary irradiation.

Fig 1. CONSORT diagram showing patient population from which semen analysis data were derived. HPT XRT, hypothalamic-pituitary irradiation.
  • Green DM, Zhu L, Zhang N, Sklar CA, Ke RW, Kutteh WH, Klosky JL, Spunt SL, Metzger ML, Navid F, Srivastava D, Robison LL, Hudson MM

  • J Clin Oncol. 2013 Apr 1;31(10):1324-8.

2013-05-24

Fig 1. Kaplan-Meier overall survival stratified by disease status.

Fig 1. Kaplan-Meier overall survival stratified by disease status.
  • Gerber NK, Wexler LH, Singer S, Alektiar KM, Keohan ML, Shi W, Zhang Z, Wolden S

  • Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):58-63.

2013-05-28

Fig 1. Net benefit plotted against threshold probability for molecular markers of prostate cancer. Gray line: biopsy all men. Thick black line: biopsy no men. Thin black line: biopsy if FT test is positive. Dashed line: biopsy if HK test is positive.

Fig 1. Net benefit plotted against threshold probability for molecular markers of prostate cancer. Gray line: biopsy all men. Thick black line: biopsy no men. Thin black line: biopsy if FT test is positive. Dashed line: biopsy if HK test is positive.
  • Vickers AJ, Cronin AM, Gönen M

  • Stat Med. 2013 May 20;32(11):1865-76.

2013-05-29

Fig 1. CSC robustly maintains oxygen consumption rate constancy in a minimal ETC.

Fig 1. CSC robustly maintains oxygen consumption rate constancy in a minimal ETC.
  • Kueh HY, Niethammer P, Mitchison TJ

  • Biophys J. 2013 Mar 19;104(6):1338-48.

2013-05-31

Fig 1a. Experimental strategy to test connectivity between a protein-coding gene and a downstream lincRNA.

Fig 1a. Experimental strategy to test connectivity between a protein-coding gene and a downstream lincRNA.
  • Miura P, Shenker S, Andreu-Agullo C, Westholm JO, Lai EC

  • Genome Res. 2013 May;23(5):812-25.

2013-06-03

Fig 1. Recurrence-free survival.

Fig 1. Recurrence-free survival.
  • Herr HW, Dalbagni G

  • BJU Int. 2013 May;111(6):984-7.

2013-06-04

Fig 1. Sagittal (A) and axial (B) slices from a 3D-conformal radiation therapy plan.

Fig 1. Sagittal (A) and axial (B) slices from a 3D-conformal radiation therapy plan.
  • Milgrom SA, Yahalom J

  • Leuk Lymphoma. 2013 Jun;54(6):1208-11.

2013-06-05

Fig 6. Cross-sectional OCT and en face RCM images of the EpiDermFT Skin Model.

Fig 6. Cross-sectional OCT and en face RCM images of the EpiDermFT Skin Model.
  • Iftimia N, Ferguson RD, Mujat M, Patel AH, Zhang EZ, Fox W, Rajadhyaksha M

  • Biomed Opt Express. 2013 Apr 8;4(5):680-95.
Open Access button

2013-06-06

Fig 1. Flow Diagram of Studies. Two patients who were alive at the end of protocol 1 but who did not participate in protocol 3 were excluded.

Fig 1. Flow Diagram of Studies. Two patients who were alive at the end of protocol 1 but who did not participate in protocol 3 were excluded.
  • Rini BI, de La Motte Rouge T, Harzstark AL, Michaelson MD, Liu G, Grünwald V, Ingrosso A, Tortorici MA, Bycott P, Kim S, Bloom J, Motzer RJ

  • Clin Genitourin Cancer. 2013 Jun;11(2):107-14.

2013-06-07

Fig 1. A 58-year-old woman with stage IV breast cancer presented with an enlarging left parasternal chest wall mass.

Fig 1. A 58-year-old woman with stage IV breast cancer presented with an enlarging left parasternal chest wall mass.
  • Ulaner GA, D'Andrea G, Cody HS 3rd

  • Clin Nucl Med. 2013 Jun;38(6):480-1.

2013-06-10

Fig 4. A) Coronal MIP of 18F-FDG PET images of a 44 year old woman diagnosed with recurrent cervical cancer initially treated with definitive chemoradiotherapy. The patient was without evidence of disease on her last follow-up. B, C) Transverse CT and fused PET/CT images, with the recurrence (arrow), D, E) Sagittal CT and fused PET/CT images illustrating the recurrence (arrow).

Fig 4. A) Coronal MIP of 18F-FDG PET images of a 44 year old woman diagnosed with recurrent cervical cancer initially treated with definitive chemoradiotherapy. The patient was without evidence of disease on her last follow-up. B, C) Transverse CT and fused PET/CT images, with the recurrence (arrow), D, E) Sagittal CT and fused PET/CT images illustrating the recurrence (arrow).
  • Burger IA, Vargas HA, Donati OF, Andikyan V, Sala E, Gonen M, Goldman DA, Chi DS, Schöder H, Hricak H

  • Gynecol Oncol. 2013 Jun;129(3):586-92.

2013-06-11

Fig 1. Localization and regulation of lipid-modified proteins.Conceptual diagram of representative proteins modified with various lipophilic groups.

Fig 1. Localization and regulation of lipid-modified proteins.Conceptual diagram of representative proteins modified with various lipophilic groups.
  • Resh MD

  • Curr Biol. 2013 May 20;23(10):R431-5.

2013-06-12

Fig 1. The estimated numbers of cancer survivors in (Top) the United States in 2010 and (Bottom) the European Union in 2008 are compared with the numbers of new cancer diagnoses and deaths for the same years.

Fig 1. The estimated numbers of cancer survivors in (Top) the United States in 2010 and (Bottom) the European Union in 2008 are compared with the numbers of new cancer diagnoses and deaths for the same years.
  • Stubblefield MD, Hubbard G, Cheville A, Koch U, Schmitz KH, Dalton SO

  • Cancer. 2013 Jun 1;119 Suppl 11:2170-8.

2013-06-13

Figure 2. Ventral folding morphogenesis encompasses multiple concurrent tissue rearrangements

Figure 2. Ventral folding morphogenesis encompasses multiple concurrent tissue rearrangements
  • Gavrilov S, Lacy E

  • Curr Opin Genet Dev. 2013 May 21.

2013-06-14

Figure 1. Monthly and cumulative accrual to Cancer and Leukemia Group B 100104.

Figure 1. Monthly and cumulative accrual to Cancer and Leukemia Group B 100104.
  • Giralt S, McCarthy PL, Anderson KC, Carter SL, Richardson PG, Rajkumar SV, Laport GG, Stadtmauer EA, Pasquini MC, Horowitz MM

  • Biol Blood Marrow Transplant. 2013 Jun;19(6):858-9.

2013-06-17

Figure 1. Molecular hybridization of lead compounds 1 and 2 to create a new template.

Figure 1. Molecular hybridization of lead compounds 1 and 2 to create a new template.
  • Patel BA, Krishnan R, Khadtare N, Gurukumar KR, Basu A, Arora P, Bhatt A, Patel MR, Dana D, Kumar S, Kaushik-Basu N, Talele TT

  • Bioorg Med Chem. 2013 Jun 1;21(11):3262-71.

2013-06-18

Fig 2. Kaplan–Meier analysis of (A) PFS (data cut-off of September 2010) and (B) overall survival (data cut-off of February 2012).

Fig 2. Kaplan–Meier analysis of (A) PFS (data cut-off of September 2010) and (B) overall survival (data cut-off of February 2012).
  • Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA

  • Clin Cancer Res. 2013 May 15;19(10):2745-2754.

2013-06-19

Fig 1. Kaplan–Meier curves illustrating cumulative locoregional (LR) recurrence free probability in pathologically downstaged N0 versus N1 disease.

Fig 1. Kaplan–Meier curves illustrating cumulative locoregional (LR) recurrence free probability in pathologically downstaged N0 versus N1 disease.
  • Amini A, Lou F, Correa AM, Baldassarre R, Rimner A, Huang J, Roth JA, Swisher SG, Vaporciyan AA, Lin SH

  • Ann Surg Oncol. 2013 Jun;20(6):1934-40.
Open Access button

2013-06-20

Fig 4. p-Y393-AGO2 enhances cell survival and invasiveness under hypoxia and correlates with poorer overall survival in breast cancer patients. (d) Representative images of immunohistochemical staining of p-Y393-AGO2 in human breast tumour and its adjacent normal tissue.

Fig 4. p-Y393-AGO2 enhances cell survival and invasiveness under hypoxia and correlates with poorer overall survival in breast cancer patients. (d) Representative images of immunohistochemical staining of p-Y393-AGO2 in human breast tumour and its adjacent normal tissue.
  • Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim SO, Du Y, Wang Y, Chang WC, Chen CH, Hsu JL, Wu Y, Lam YC, James BP, Liu X, Liu CG, Patel DJ, Hung MC

  • Nature. 2013 May 16;497(7449):383-7.

2013-06-21

Fig 1. Patterns of recurrence and sites of metastasis in primary leiomyosarcoma. (b). Sites of metastasis in all patients; site of first DR (i) and all DR (ii).

Fig 1. Patterns of recurrence and sites of metastasis in primary leiomyosarcoma. (b). Sites of metastasis in all patients; site of first DR (i) and all DR (ii).
  • Gladdy RA, Qin LX, Moraco N, Agaram NP, Brennan MF, Singer S

  • Ann Surg Oncol. 2013 Jun;20(6):1851-7.

2013-06-24

Fig 2. Elastography of irreversible electroporation (IRE) ablation.

Fig 2. Elastography of irreversible electroporation (IRE) ablation.
  • Au JT, Kingham TP, Jun K, Haddad D, Gholami S, Mojica K, Monette S, Ezell P, Fong Y.

  • Surgery. 2013 Jun;153(6):787-93.

2013-06-25

Fig. 1. Tumor-to-organ ratios in terms of FDG uptake in mice with PC3 xenografts.

Fig. 1. Tumor-to-organ ratios in terms of FDG uptake in mice with PC3 xenografts.
  • Andersen KF, Divilov V, Koziorowski J, Pillarsetty N, Lewis JS

  • Nucl Med Biol. 2013 May;40(4):524-8.

2013-06-26

Fig 1. Percentage of Patients Meeting Recommended Daily Intake For Each Identified Food Group.

Fig 1. Percentage of Patients Meeting Recommended Daily Intake For Each Identified Food Group.
  • Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JA

  • Clin Colorectal Cancer. 2013 Jun;12(2):95-102.

2013-06-27

Fig 1a. Expression of Hoxd10 during bud outgrowth (bottom) with a schematic illustration of the early (green) and late (purple) phases of expression (top).

Fig 1a. Expression of Hoxd10 during bud outgrowth (bottom) with a schematic illustration of the early (green) and late (purple) phases of expression (top).
  • Andrey G, Montavon T, Mascrez B, Gonzalez F, Noordermeer D, Leleu M, Trono D, Spitz F, Duboule D

  • Science. 2013 Jun 7;340(6137):1234167.

2013-06-28

Fig 1a. Transverse in-phase (a TE, 4.2 ms) chemical shift 1.5-T MR images in a 56-year-old man with a clear cell carcinoma.

Fig 1a. Transverse in-phase (a TE, 4.2 ms) chemical shift 1.5-T MR images in a 56-year-old man with a clear cell carcinoma.
  • Karlo CA, Donati OF, Burger IA, Zheng J, Moskowitz CS, Hricak H, Akin O

  • Eur Radiol. 2013 Jun;23(6):1738-44.

2013-07-01

Fig 1b. A positive RET FISH break-apart test. Split green and red signals indicate the presence of a RET fusion.

Fig 1b. A positive RET FISH break-apart test. Split green and red signals indicate the presence of a RET fusion.
  • Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, Ross J, Miller V, Ginsberg M, Zakowski MF, Kris MG, Ladanyi M, Rizvi N

  • Cancer Discov. 2013 Jun;3(6):630-5.